Core Insights - The new medical insurance directory, effective from January 1, 2025, includes three innovative drugs developed by Kelun-Biotech, namely Lukanasatuzumab (Jiatailai), Cetuximab N01 (Daitailai), and Tagolizumab (Ketailai) [1][2] - Lukanasatuzumab is the first domestically developed ADC approved for treating advanced triple-negative breast cancer (TNBC) and has received approval for a second indication for EGFR mutation-positive non-small cell lung cancer (NSCLC) [1] - The inclusion of these drugs in the medical insurance directory significantly reduces treatment costs and alleviates the financial burden on patients, making life-saving treatments more accessible [2] Company Insights - Kelun-Biotech's CEO, Dr. Ge Junyou, emphasized the company's commitment to addressing unmet clinical needs and providing affordable alternatives to existing treatments, aiming to prevent poverty caused by medical expenses [2] - The company positions itself as a leader in innovative drug development, focusing on filling gaps in treatment options for serious conditions [1][2] Industry Insights - The new insurance directory reflects a broader trend in the healthcare industry towards making innovative treatments more accessible through reimbursement mechanisms [2] - The approval of Lukanasatuzumab and its subsequent indications highlights the growing importance of domestic pharmaceutical innovation in addressing critical healthcare challenges in China [1]

Core Insights - The company reported a revenue of RMB 950 million for the six months ending June 30, 2025, representing a year-on-year decrease of 31.3% [1] - Research and development expenses amounted to RMB 612 million, down 6.3% year-on-year [1] - The company incurred a loss attributable to equity shareholders of RMB 145 million, with a loss per share of RMB 0.64 [1] Financial Performance - Total commercial sales for the first half of 2025 reached RMB 309.8 million, with 97.6% of sales coming from the product "佳泰莱" [1] - All accounts receivable from drug sales were collected within the payment period, indicating efficient cash flow management [1] Product Development and Pipeline - The company has received marketing approvals for sac-TMT (佳泰莱), Tagolizumab (科泰莱), and Cetuximab N01 (达泰莱) and has commenced commercialization [1] - The company anticipates launching "博度曲妥珠单抗" (舒泰莱) in the Chinese market in the second half of 2025, pending regulatory communication and approval [1] - The company is a pioneer in developing ADCs and has over ten years of experience in this field, with a proprietary platform for ADC and novel conjugated drugs [2] Manufacturing and Quality Management - The company possesses end-to-end manufacturing capabilities that comply with cGMP standards and a comprehensive quality management system to support drug development [2] - The company benefits from the extensive experience, industry relationships, and network of its controlling shareholder, 科伦药业 (002422), which enhances its commercialization infrastructure and market pipeline [2]